Shares of Chimerix Inc (NASDAQ:CMRX) have received an average rating of “Hold” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $7.67.
CMRX has been the subject of a number of recent research reports. ValuEngine lowered shares of Chimerix from a “sell” rating to a “strong sell” rating in a report on Thursday, November 9th. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a report on Friday, November 10th. HC Wainwright initiated coverage on shares of Chimerix in a report on Friday, February 2nd. They issued a “buy” rating and a $10.00 target price for the company. Finally, JPMorgan Chase & Co. lowered shares of Chimerix from a “neutral” rating to an “underweight” rating in a report on Wednesday, February 14th.
In related news, insider Linda M. Richardson sold 19,833 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $4.47, for a total value of $88,653.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.40% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. bought a new stake in Chimerix in the fourth quarter worth $137,000. Voya Investment Management LLC lifted its position in Chimerix by 18.3% in the second quarter. Voya Investment Management LLC now owns 29,203 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 4,526 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Chimerix by 8.3% in the second quarter. The Manufacturers Life Insurance Company now owns 39,628 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 3,042 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Chimerix in the fourth quarter worth $280,000. Finally, Nationwide Fund Advisors lifted its position in shares of Chimerix by 70.3% during the third quarter. Nationwide Fund Advisors now owns 60,567 shares of the biopharmaceutical company’s stock worth $318,000 after purchasing an additional 24,994 shares during the last quarter. Institutional investors own 72.69% of the company’s stock.
Chimerix (CMRX) traded up $0.07 during mid-day trading on Wednesday, hitting $5.02. 251,200 shares of the company were exchanged, compared to its average volume of 271,088. Chimerix has a 1 year low of $4.17 and a 1 year high of $6.64. The stock has a market capitalization of $236.58, a price-to-earnings ratio of -3.51 and a beta of 1.42.
TRADEMARK VIOLATION NOTICE: “Brokerages Set Chimerix Inc (CMRX) PT at $7.67” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/19/brokerages-set-chimerix-inc-cmrx-pt-at-7-67.html.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.